Vitamin K antagonist + Apixaban
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Atrial Fibrillation
Conditions
Atrial Fibrillation
Trial Timeline
Dec 1, 2014 → Sep 1, 2017
NCT ID
NCT02227550About Vitamin K antagonist + Apixaban
Vitamin K antagonist + Apixaban is a approved stage product being developed by Pfizer for Atrial Fibrillation. The current trial status is completed. This product is registered under clinical trial identifier NCT02227550. Target conditions include Atrial Fibrillation.
What happened to similar drugs?
20 of 20 similar drugs in Atrial Fibrillation were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02227550 | Approved | Completed |
Competing Products
20 competing products in Atrial Fibrillation